Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1928 1
1931 1
1932 1
1951 1
1952 1
1972 2
1975 9
1976 15
1977 13
1978 8
1979 17
1980 15
1981 20
1982 19
1983 22
1984 28
1985 30
1986 32
1987 20
1988 41
1989 46
1990 42
1991 54
1992 51
1993 74
1994 93
1995 113
1996 101
1997 128
1998 131
1999 124
2000 163
2001 152
2002 156
2003 160
2004 188
2005 189
2006 195
2007 210
2008 223
2009 241
2010 294
2011 324
2012 364
2013 413
2014 418
2015 429
2016 489
2017 518
2018 628
2019 804
2020 1118
2021 987
Text availability
Article attribute
Article type
Publication date

Search Results

8,915 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein S. Burstein S. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7. Bioorg Med Chem. 2015. PMID: 25703248 Review.
This was no doubt due to the belief that activity meant psychoactivity that was shown by THC and not by CBD. In retrospect this must be seen as unfortunate since a number of actions of CBD with potential therapeutic benefit were downplayed for many years. ...Topics …
This was no doubt due to the belief that activity meant psychoactivity that was shown by THC and not by CBD. In retrospect this must …
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Results: CBD was shown to have anxiolytic, antipsychotic and neuroprotective properties. ...Discussion: CBD is an useful and promising molecule that may help patients with a number of clinical conditions. ...
Results: CBD was shown to have anxiolytic, antipsychotic and neuroprotective properties. ...Discussion: CBD is an useful and p …
Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Bonaccorso S, et al. Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Neurotoxicology. 2019. PMID: 31412258 Review.
However, CBD may present with a different activity compared with the psychotomimetic THC. Most typically, CBD is reported to be used in some medical conditions, including chronic pain. ...
However, CBD may present with a different activity compared with the psychotomimetic THC. Most typically, CBD is reported to b …
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM. White CM. J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7. J Clin Pharmacol. 2019. PMID: 30730563 Review.
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...The control of refractory seizures is a clear exception, with strong evidence of CBD's benefit. Acute CBD dosing before anxiety-provoking events like public spea …
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...The control of refractory seizures …
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.
Watt G, Karl T. Watt G, et al. Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. eCollection 2017. Front Pharmacol. 2017. PMID: 28217094 Free PMC article. Review.
Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. ...The studies provide "proof of principle" that CBD and possibly CBD-THC combinations are valid candidates for novel AD therapies. ...
Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. ...The studies provide "proof …
Cannabidiol (CBD).
Meissner H, Cascella M. Meissner H, et al. 2021 Jul 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 Jul 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32310508 Free Books & Documents. Review.
CBD is a medication used to manage and treat the seizure disorders Lennox-Gastaut syndrome and Dravet syndrome. This activity describes the indications, action, and contraindications for CBD as a valuable agent in the treatment and management of Lennox-Gastaut syndr
CBD is a medication used to manage and treat the seizure disorders Lennox-Gastaut syndrome and Dravet syndrome. This activity describ
Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S, Kloiber S, Le Foll B. Elsaid S, et al. Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28. Prog Mol Biol Transl Sci. 2019. PMID: 31601406 Review.
Moreover, CBD was shown to reduce addictive effects of some drugs of abuse. ...Currently, there are no human studies that investigated the effects of CBD in either Alzheimer's disease or unipolar depression, warranting further investigation in this area, considering …
Moreover, CBD was shown to reduce addictive effects of some drugs of abuse. ...Currently, there are no human studies that investigate …
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence.
Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. Boyaji S, et al. Curr Pain Headache Rep. 2020 Jan 24;24(2):4. doi: 10.1007/s11916-020-0835-4. Curr Pain Headache Rep. 2020. PMID: 31980957 Review.
Since there are currently no approved pharmaceutical products that contain CBD alone for the management of pain, this review focused on nabiximols (which is a combined product of THC/CBD in a 1:1 ratio) as the only pharmaceutical product available that contains C
Since there are currently no approved pharmaceutical products that contain CBD alone for the management of pain, this review focused …
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.
Brown JD, Winterstein AG. Brown JD, et al. J Clin Med. 2019 Jul 8;8(7):989. doi: 10.3390/jcm8070989. J Clin Med. 2019. PMID: 31288397 Free PMC article. Review.
Given CBD use among patients with complex conditions and treatment regimens, as well as its expanded consumer use, awareness of potential safety issues with CBD is needed. ...These effects should be considered in the risk-benefit assessment of CBD therapy and …
Given CBD use among patients with complex conditions and treatment regimens, as well as its expanded consumer use, awareness of poten …
Towards Better Delivery of Cannabidiol (CBD).
Millar SA, Maguire RF, Yates AS, O'Sullivan SE. Millar SA, et al. Pharmaceuticals (Basel). 2020 Aug 28;13(9):219. doi: 10.3390/ph13090219. Pharmaceuticals (Basel). 2020. PMID: 32872355 Free PMC article. Review.
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. ...This revie …
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is h …
8,915 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page